{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:06:33Z","timestamp":1790787993049,"version":"4.1.0"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T00:00:00Z","timestamp":1608249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Anemia is a clinical feature of chronic kidney disease (CKD). Most common causes are iron and erythropoietin deficiency. The last two decades have yielded significant advances in understanding iron balance's physiology, including iron trafficking and the crosstalk between iron, oxygen, and erythropoiesis. This knowledge sheds new light on the regulation and disturbance of iron homeostasis in CKD and holds the promise for developing new diagnostic and therapeutic tools to improve the management of iron disorders. Hepcidin\u2013ferroportin axis has a central role in regulating body iron balance and coordinating communication between tissues and cells that acquire, store, and utilize iron. Recent research has revealed a bidirectional relationship between fibroblast growth factor 23 (FGF23) and iron status, anemia, and inflammation, as well as the role of erythroferrone (ERFE) in iron homeostasis. However, ERFE concentrations and actions are not well-characterized in CKD patients. Studies on ERFE in CKD are limited with slightly conflicting results. Despite general interest in iron metabolism in kidney diseases, studies on the less prevalent renal replacement therapy mode, such as peritoneal dialysis or hemodiafiltration, are scarce. Slightly more was published on hemodialysis. There are several novel options on the horizon; however, clinical data are limited. One should be aware of the potential risks and benefits of the novel, sophisticated therapies. An inhibition of hepcidin on the different pathways might be also a viable adjunctive therapeutic option in other clinical situations.<\/jats:p>","DOI":"10.3389\/fmed.2020.565135","type":"journal-article","created":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:45:42Z","timestamp":1608270342000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Iron and Chronic Kidney Disease: Still a Challenge"],"prefix":"10.3389","volume":"7","author":[{"given":"Ewa","family":"Wojtaszek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Glogowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Malyszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS ONE."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanism of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J Am Soc Nephrol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am J Kidney Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1185\/030079904X2763","article-title":"The prevalence of anemia in patients with chronic kidney disease","volume":"20","author":"McClellan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"B5","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1093\/ckj\/sfz091","article-title":"Anemia and iron deficiency among chronic kidney disease Stages 3-5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated","volume":"13","author":"Wong","year":"2019","journal-title":"Clin Kiney J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/nep.12493","article-title":"Anemia management and mortality risk in newly visiting patients with chronic kidney disease in Japan: the CKD-ROUTE study","volume":"20","author":"Imori","year":"2015","journal-title":"Nephrology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.kint.2019.04.029","article-title":"An increased mortality risk is associated with abnormal iron status in diabetic and non-diabetic Veterans with predialysis chronic kidney disease","volume":"96","author":"Cho","year":"2019","journal-title":"Kidney Int."},{"key":"B8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s12882-018-1021-3","article-title":"Association of different iron deficiency cutoffs with adverse outcomes in chronic kidney disease","volume":"19","author":"Eisenga","year":"2018","journal-title":"BMC Nephrol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/tri.12821","article-title":"Iron deficiency anemia and mortality in renal transplant recipients","volume":"29","author":"Eisenga","year":"2016","journal-title":"Transpl Int."},{"key":"B10","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/bjh.15403","article-title":"Advances in understanding iron metabolism and its crosstalk with erythropoiesis","volume":"182","author":"Camashella","year":"2018","journal-title":"Brit J Haematol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1093\/ndt\/gft443","article-title":"The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients","volume":"29","author":"Zumbrennen-Bullough","year":"2014","journal-title":"Nephrol Dial Transpl."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4754","DOI":"10.1182\/blood-2010-05-286260","article-title":"Detection, evaluation and management of iron restricted erythropoiesis","volume":"116","author":"Goodnough","year":"2010","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"260","DOI":"10.3324\/haematol.2019.232124","article-title":"Iron metabolism and iron disorders revisited in the hepcidin era","volume":"105","author":"Camaschella","year":"2020","journal-title":"Hematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/ki.2009.460","article-title":"Hypoxia inducible factor\u22122alpha expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxiainducible factor stabilization","volume":"77","author":"Paliege","year":"2010","journal-title":"Kidney Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2018-06-857995","article-title":"Erythroferrone inhibits the induction of hepcidin by BMP 6","volume":"132","author":"Arezes","year":"2018","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/blood-2016-12-759423","article-title":"Smad1\/5 is required for erythropoietin\u2013mediated suppression of hepcidine in mice","volume":"130","author":"Wang","year":"2017","journal-title":"Blood."},{"key":"B18","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2012-11-427765","article-title":"The gut in iron homeostasis: role of HIF-2 under normal and pathological conditions","volume":"122","author":"Mastrogiannaki","year":"2013","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1172\/JCI122359","article-title":"Hepatic hepcidin\/intestinal HIF- 2alpha axis maintains iron absorption during iron deficiency and overload","volume":"129","author":"Schwartz","year":"2019","journal-title":"J Clin Invest."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/hdi.12542","article-title":"Overview of iron metabolism in health and disease","author":"Dev","year":"2017","journal-title":"Hemodial Int."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1681\/ASN.2015010052","article-title":"The labile side of iron supplementation in CKD","volume":"26","author":"Slotki","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.cmet.2011.08.015","article-title":"Activation of the HIF propyl hydroxylase by the iron chaperones PCBP1 and PCBP2","volume":"14","author":"Nandal","year":"2011","journal-title":"Cell Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1182\/blood-2011-03-345066","article-title":"Pharmacologic inhibition of hepcidin expression reverses anemia of chronic inflammation in rats","volume":"118","author":"Theurl","year":"2011","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.exphem.2015.08.010","article-title":"Exp Hematol","volume":"44","author":"Eleftheriadis","year":"2016"},{"key":"B25","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1093\/ndt\/gfx252","article-title":"The uremic toxin indoxyl sulphate interferes with iron metabolism by regulating hepcidin in chronic kidney disease","volume":"33","author":"Hamano","year":"2018","journal-title":"Nephrol Dial Transpl."},{"key":"B26","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.kint.2018.03.023","article-title":"Crossroads of metabolism in CKD","volume":"94","author":"Suzuki","year":"2018","journal-title":"Kidney Int."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e0151601","DOI":"10.1371\/journal.pone.0151601","article-title":"Association among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis","volume":"11","author":"Honda","year":"2016","journal-title":"PLoS ONE."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.3324\/haematol.2017.181743","article-title":"Levels of the erythropoietin -responsive hormone erythroferrone in mice and humans with chronic kidney disease","volume":"103","author":"Hanudel","year":"2018","journal-title":"Hematologica."},{"key":"B29","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/jcm8040523","article-title":"Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and CKD patients: a two cohort study","volume":"8","author":"Spoto","year":"2019","journal-title":"J Clin Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.2215\/CJN.08161109","article-title":"Reduction of serum hepcidin by hemodialysis in pediatric and adult patients","volume":"5","author":"Zaritsky","year":"2010","journal-title":"Clin J Am Soc Nephrol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1038\/s41598-017-04664-y","article-title":"Serum hepcidin may be a novel uremic toxin, which may be related to erythropoietin resistance","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3109\/08860220903216071","article-title":"Type of renal replacement therapy and residual renal function may affect prohepcididn and hepcidin","volume":"31","author":"Malyszko","year":"2009","journal-title":"Ren Failure."},{"key":"B33","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ndt\/gfu345","article-title":"High-volume online haemodiafiltration improves erythropoiesis-stimulating agent (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study","volume":"30","author":"Panichi","year":"2015","journal-title":"Nephrol Dial Transpl."},{"key":"B34","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000336482","article-title":"Hemodiafiltration improve plasma 25- hepcidin levels: a prospective, randomized, blinded, cross-over study comparing hemodialysis and hemodiafiltration","volume":"2","author":"Stefansson","year":"2012","journal-title":"Nephron Extra."},{"key":"B35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1159\/000441437","article-title":"Effect of a more permeable dialysis membrane on ESA resistance in hemodialysis patients\u2014a pilot investigation","volume":"41","author":"Teatini","year":"2016","journal-title":"Blood Purif."},{"key":"B36","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/ph12030123","article-title":"Unraveling hepcidin plasma protein binding: evidence from peritoneal equilibration testing","volume":"12","author":"Diepeveen","year":"2019","journal-title":"Pharmaceutic"},{"key":"B37","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1152\/ajprenal.00359.2016","article-title":"Ironing out the cross talk between FGF23 and inflammation","volume":"312","author":"David","year":"2017","journal-title":"Am J Physiol Renal Physiol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/ki.2015.290","article-title":"Inflammation and functional iron deficiency regulate fibroblast growth factor 23 production","volume":"89","author":"David","year":"2016","journal-title":"Kidney Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"7249","DOI":"10.1038\/s41598-018-25439-z","article-title":"Circulating fibroblast growth factor 23 levels are associated with an increased risk of anemia development in patients with non-dialysis chronic kidney disease","volume":"8","author":"Nam","year":"2018","journal-title":"Sci Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/ndt\/gfy\/189","article-title":"Effects of erythropoietin on fibroblast growth factor 23 in mice and humans","volume":"34","author":"Hanudel","year":"2018","journal-title":"Nephrol Dial Transpl."},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfx043","article-title":"Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions","author":"Macdougall","year":"2017","journal-title":"Clin Kidney J."},{"key":"B43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Soc Nephrol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1053\/j.ackd.2019.05.002","article-title":"Novel oral iron therapies for iron deficiency anemia in chronic kidney disease","volume":"26","author":"Pergola","year":"2019","journal-title":"Adv Chronic Kidney Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1681\/ASN.2016101053","article-title":"Effects of ferric citrate in patients with non-dialysis-dependent CKD and iron deficiency anemia","volume":"28","author":"Fishbane","year":"2017","journal-title":"J Am Soc Nephrol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double blind, placebo controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"Am J Kidney Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"E154","DOI":"10.1002\/ajh.25088","article-title":"Hemoglobin response to ferric citrate in patients with non-dialysis-dependent chronic kidney disease and iron deficiency anemia","volume":"93","author":"Pergola","year":"2018","journal-title":"Am J Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.5414\/CN108924","article-title":"The safety of achieved iron stores and their effect on iv iron and ESA use: post-hoc results from a randomized trial of ferric citrate as phosphate binder in dialysis","volume":"87","author":"Umanath","year":"2017","journal-title":"Clin Nephrol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1182\/blood-2010-10-313064","article-title":"Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation","volume":"117","author":"Steinbicker","year":"2011","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.cellsig.2011.06.019","article-title":"The specificities of small molecule inhibitors of the TGFss andBMP pathways","volume":"23","author":"Vogt","year":"2011","journal-title":"Cell Signal"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","article-title":"Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease","volume":"116","author":"Song","year":"2010","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1200\/JCO.2009.27.2377","article-title":"Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman'sdisease","volume":"28","author":"van Rhee","year":"2010","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13877","article-title":"Targeting the hepcidin-ferroportin pathway inanemia of chronic kidney disease","author":"Sheetz","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting Hypoxia-Inducible Factors for the treatment of anemia in chronic kidney disease patients","volume":"45","author":"Locatelli","year":"2017","journal-title":"Am J Nephrol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia\u2013inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592)for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin J Am Soc Nephrol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1681\/ASN.2015030241","article-title":"Roxadustat (FG-4592): correction of anemia in incident dialysis patients","volume":"27","author":"Besarab","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.2215\/CJN.02510218","article-title":"Effects of Molidustat in the treatment of anemia in CKD","volume":"17","author":"Macdougall","year":"2019","journal-title":"Clin J Am Soc Nephrol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Kidney Int","volume":"90","author":"Pergola","year":"2016"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studied of oral hypoxia inducible factor prolyl hydroxylase inhibitor GSK 1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol."},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2017.00259","article-title":"Hypoxia induced factor in chronic kidney disease: friend or foe?","author":"Li","year":"","journal-title":"Front Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0212023","DOI":"10.1371\/journal.pone.0212023","article-title":"First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis","volume":"14","author":"Renders","year":"2019","journal-title":"PLoS ONE."},{"key":"B62","doi-asserted-by":"publisher","first-page":"3752","DOI":"10.1096\/fj.201700667R","article-title":"Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia","volume":"32","author":"Agoro","year":"2018","journal-title":"Faseb J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.565135\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,18]],"date-time":"2020-12-18T05:45:43Z","timestamp":1608270343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2020.565135\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":62,"alternative-id":["10.3389\/fmed.2020.565135"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2020.565135","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,18]]},"article-number":"565135"}}